Rhythm Pharmaceuticals, Inc. RYTM Cash and cash equivalents, end of period
Cash and cash equivalents, end of period at other companies
Other financials
Where this comes from
Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations.
The official record: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rhythm Pharmaceuticals, Inc.'s cash and cash equivalents, end of period.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rhythm Pharmaceuticals, Inc.'s cash and cash equivalents, end of period?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported cash and cash equivalents, end of period of $62.74M in Q1 2026.